These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 34785111)

  • 1. Minimal residual disease and outcome characteristics in infant KMT2A-germline acute lymphoblastic leukaemia treated on the Interfant-06 protocol.
    Stutterheim J; de Lorenzo P; van der Sluis IM; Alten J; Ancliffe P; Attarbaschi A; Aversa L; Boer JM; Biondi A; Brethon B; Diaz P; Cazzaniga G; Escherich G; Ferster A; Kotecha RS; Lausen B; Leung AW; Locatelli F; Silverman L; Stary J; Szczepanski T; van der Velden VHJ; Vora A; Zuna J; Schrappe M; Valsecchi MG; Pieters R
    Eur J Cancer; 2022 Jan; 160():72-79. PubMed ID: 34785111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Implications of Minimal Residual Disease Detection in Infants With
    Stutterheim J; van der Sluis IM; de Lorenzo P; Alten J; Ancliffe P; Attarbaschi A; Brethon B; Biondi A; Campbell M; Cazzaniga G; Escherich G; Ferster A; Kotecha RS; Lausen B; Li CK; Lo Nigro L; Locatelli F; Marschalek R; Meyer C; Schrappe M; Stary J; Vora A; Zuna J; van der Velden VHJ; Szczepanski T; Valsecchi MG; Pieters R
    J Clin Oncol; 2021 Feb; 39(6):652-662. PubMed ID: 33405950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A risk-stratified therapy for infants with acute lymphoblastic leukemia: a report from the JPLSG MLL-10 trial.
    Tomizawa D; Miyamura T; Imamura T; Watanabe T; Moriya Saito A; Ogawa A; Takahashi Y; Hirayama M; Taki T; Deguchi T; Hori T; Sanada M; Ohmori S; Haba M; Iguchi A; Arakawa Y; Koga Y; Manabe A; Horibe K; Ishii E; Koh K
    Blood; 2020 Oct; 136(16):1813-1823. PubMed ID: 32845001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic characteristics and treatment outcome in infants with KMT2A germline B-cell precursor acute lymphoblastic leukemia: Results of MLL-Baby protocol.
    Popov A; Tsaur G; Permikin Z; Henze G; Verzhbitskaya T; Plekhanova O; Nokhrina E; Valochnik A; Sibiryakov P; Zerkalenkova E; Olshanskaya Y; Gindina T; Movchan L; Shorikov E; Streneva O; Khlebnikova O; Makarova O; Arakaev O; Boichenko E; Kondratchik K; Ponomareva N; Lapotentova E; Aleinikova O; Miakova N; Novichkova G; Karachunskiy A; Fechina L
    Pediatr Blood Cancer; 2023 Apr; 70(4):e30204. PubMed ID: 36715125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol.
    Van der Velden VH; Corral L; Valsecchi MG; Jansen MW; De Lorenzo P; Cazzaniga G; Panzer-Grümayer ER; Schrappe M; Schrauder A; Meyer C; Marschalek R; Nigro LL; Metzler M; Basso G; Mann G; Den Boer ML; Biondi A; Pieters R; Van Dongen JJ;
    Leukemia; 2009 Jun; 23(6):1073-9. PubMed ID: 19212338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study.
    Pieters R; De Lorenzo P; Ancliffe P; Aversa LA; Brethon B; Biondi A; Campbell M; Escherich G; Ferster A; Gardner RA; Kotecha RS; Lausen B; Li CK; Locatelli F; Attarbaschi A; Peters C; Rubnitz JE; Silverman LB; Stary J; Szczepanski T; Vora A; Schrappe M; Valsecchi MG
    J Clin Oncol; 2019 Sep; 37(25):2246-2256. PubMed ID: 31283407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. No benefit of Interfant protocols compared to BFM-based protocols for infants with acute lymphoblastic leukemia. Results from an institution in Argentina.
    Pennella CL; Deu MA; Rossi JG; Baialardo EM; Alonso CN; Rubio P; Guitter MR; La Rosa CGS; Alfaro EM; Zubizarreta PA; Felice MS
    Pediatr Blood Cancer; 2020 Oct; 67(10):e28624. PubMed ID: 32729239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia.
    van der Sluis IM; de Lorenzo P; Kotecha RS; Attarbaschi A; Escherich G; Nysom K; Stary J; Ferster A; Brethon B; Locatelli F; Schrappe M; Scholte-van Houtem PE; Valsecchi MG; Pieters R
    N Engl J Med; 2023 Apr; 388(17):1572-1581. PubMed ID: 37099340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of minimal residual disease measured by fusion-gene transcript in infants with KMT2A-rearranged acute lymphoblastic leukaemia treated according to the MLL-Baby protocol.
    Tsaur G; Popov A; Riger T; Kustanovich A; Solodovnikov A; Shorikov E; Demina A; Verzhbitskaya T; Streneva O; Makarova O; Lapotentova E; Aleinikova O; Miakova N; Boichenko E; Kondratchik K; Ponomareva N; Karachunskiy A; Roumiantsev A; Fechina L
    Br J Haematol; 2021 Jun; 193(6):1151-1156. PubMed ID: 33583020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial.
    Vora A; Goulden N; Wade R; Mitchell C; Hancock J; Hough R; Rowntree C; Richards S
    Lancet Oncol; 2013 Mar; 14(3):199-209. PubMed ID: 23395119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of minimal residual disease measurement by multicolour flow cytometry and PCR for fusion gene transcripts in infants with acute lymphoblastic leukaemia with KMT2A gene rearrangements.
    Popov A; Tsaur G; Verzhbitskaya T; Riger T; Permikin Z; Demina A; Mikhailova E; Shorikov E; Arakaev O; Streneva O; Khlebnikova O; Makarova O; Miakova N; Fominikh V; Boichenko E; Kondratchik K; Ponomareva N; Novichkova G; Karachunskiy A; Fechina L
    Br J Haematol; 2023 May; 201(3):510-519. PubMed ID: 34970734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of outcomes by early treatment responses in childhood T-cell acute lymphoblastic leukemia: a retrospective study in China.
    Wei W; Chen X; Zou Y; Chang L; An W; Wan Y; Liu T; Yang W; Chen Y; Guo Y; Zhu X
    BMC Pediatr; 2015 Jul; 15():80. PubMed ID: 26174476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimal residual disease predicts outcomes in KMT2A-rearranged but not KMT2A-germline infant acute lymphoblastic leukemia: Report from Children's Oncology Group study AALL0631.
    Faulk KE; Kairalla JA; Dreyer ZE; Carroll AJ; Heerema NA; Devidas M; Carroll WL; Raetz EA; Loh ML; Hunger SP; Borowitz M; Wang C; Guest E; Brown PA
    Pediatr Blood Cancer; 2023 May; ():e30467. PubMed ID: 37259259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of minimal residual disease on relapse in childhood acute lymphoblastic leukemia: Lessons learnt from a tertiary cancer center in India.
    Mishra V; Jain S; Anand V; Malhotra P; Tejwani N; Kapoor G
    Pediatr Hematol Oncol; 2023; 40(6):517-528. PubMed ID: 36930957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic alterations and MRD refine risk assessment for KMT2A-rearranged B-cell precursor ALL in adults: a GRAALL study.
    Kim R; Bergugnat H; Pastoret C; Pasquier F; Raffoux E; Larcher L; Passet M; Grardel N; Delabesse E; Kubetzko S; Caye-Eude A; Meyer C; Marschalek R; Lafage-Pochitaloff M; Thiebaut-Bertrand A; Balsat M; Escoffre-Barbe M; Blum S; Baumann M; Banos A; Straetmans N; Gallego-Hernanz MP; Chalandon Y; Graux C; Soulier J; Leguay T; Hunault M; Huguet F; Lhéritier V; Dombret H; Boissel N; Clappier E
    Blood; 2023 Nov; 142(21):1806-1817. PubMed ID: 37595275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low burden of minimal residual disease prior to transplantation in children with very high risk acute lymphoblastic leukaemia: The NOPHO ALL2008 experience.
    Ifversen M; Turkiewicz D; Marquart HV; Winiarski J; Buechner J; Mellgren K; Arvidson J; Rascon J; Körgvee LT; Madsen HO; Abrahamsson J; Lund B; Jonsson OG; Heilmann C; Heyman M; Schmiegelow K; Vettenranta K
    Br J Haematol; 2019 Mar; 184(6):982-993. PubMed ID: 30680711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implications of delayed bone marrow aspirations at the end of treatment induction for risk stratification and outcome in children with acute lymphoblastic leukaemia.
    Zuna J; Moericke A; Arens M; Koehler R; Panzer-Grümayer R; Bartram CR; Fischer S; Fronkova E; Zaliova M; Schrauder A; Stanulla M; Zimmermann M; Trka J; Stary J; Attarbaschi A; Mann G; Schrappe M; Cario G
    Br J Haematol; 2016 Jun; 173(5):742-8. PubMed ID: 26913693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and prognostic value of central nervous system involvement in infants with B-cell precursor acute lymphoblastic leukemia treated according to the MLL-Baby protocol.
    Popov A; Tsaur G; Permikin Z; Fominikh V; Verzhbitskaya T; Riger T; Demina A; Shorikov E; Kustanovich A; Movchan L; Streneva O; Khlebnikova O; Makarova O; Arakaev O; Solodovnikov A; Boichenko E; Kondratchik K; Ponomareva N; Lapotentova E; Aleinikova O; Miakova N; Novichkova G; Karachunskiy A; Fechina L
    Pediatr Blood Cancer; 2022 Sep; 69(9):e29860. PubMed ID: 35713168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of Childhood Noninfant Acute Lymphoblastic Leukemia With 11q23/
    Attarbaschi A; Möricke A; Harrison CJ; Mann G; Baruchel A; De Moerloose B; Conter V; Devidas M; Elitzur S; Escherich G; Hunger SP; Horibe K; Manabe A; Loh ML; Pieters R; Schmiegelow K; Silverman LB; Stary J; Vora A; Pui CH; Schrappe M; Zimmermann M;
    J Clin Oncol; 2023 Mar; 41(7):1404-1422. PubMed ID: 36256911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimal residual disease level determined by flow cytometry provides reliable risk stratification in adults with T-cell acute lymphoblastic leukaemia.
    Wang H; Zhou Y; Huang X; Zhang Y; Qian J; Li J; Li C; Li X; Lou Y; Zhu Q; Huang Y; Meng H; Yu W; Tong H; Jin J; Zhu HH
    Br J Haematol; 2021 Jun; 193(6):1096-1104. PubMed ID: 33764511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.